We deliver powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 7,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more. Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn More

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.

Learn More

Singular Genomics is driving innovation at the forefront of multiomics. Dedicated to supporting the scientific community, we focus on creating scientific advancements influenced by real-world feedback and solution-oriented development. As a publicly-traded life science technology company, we specialize in advanced next-generation sequencing (NGS) and multiomic technologies, developing products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is an innovative benchtop sequencer featuring a novel 4-color rapid sequencing-by-synthesis (SBS) chemistry and advanced engineering, providing single-day turnaround times for various applications. Our recently launched G4X Spatial Sequencer, which is an upgrade to the G4 Sequencing Platform, is designed to offer high throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.